Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent in Multiple Myeloma Patients Relapsed and/or Refractory (RRMM) to Anti-CD38 Monoclonal Antibodies (mAbs)

Aintzane Zabaleta, Laura Blanco, Peter Kim, Kamlesh Bisht, Hongfang Wang, Helgi J. Van de Velde, Marta Lasa, Luis-Esteban Tamariz-Amador, Paula Rodriguez Otero, Jesús San Miguel, Bruno Paiva, Esperanza Martín-Sánchez

Blood (2023) 142 (Supplement 1): 1921.

https://doi.org/10.1182/blood-2023-182150

Published: 2023

Journal Articles

A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent for the Treatment of Older Patients with Acute Myeloid Leukemia (AML)

Aintzane Zabaleta, Esperanza Martín-Sánchez, Laura Blanco, Peter Kim, Kamlesh Bisht, Hongfang Wang, Helgi J. Van de Velde, Tomas Jelinek, Catia Simoes, Felipe Prosper, Jesus San-Miguel, David Martinez-Cuadron, Pau Montesinos, Bruno Paiva

Blood (2023) 142 (Supplement 1): 4178.

https://doi.org/10.1182/blood-2023-184797

Published: 2023

Journal Articles

The CD38/CD3xCD28 Trispecific Antibody (SAR442257) Potentially Represents a Novel Therapeutic Strategy for Peripheral T-Cell Lymphomas

Aurélie Dupuy, Laura Pelletier, Jerome Giustiniani, Peter Kim, Kamlesh Bisht, Hongfang Wang, Helgi J. Van de Velde, Corinne Haioun, Philippe Gaulard, Nicolas Ortonne

Blood (2023) 142 (Supplement 1): 4384.

https://doi.org/10.1182/blood-2023-189088

Published: 2023

Journal Articles

High Ex Vivo Response Rates to CD38/CD28xCD3 Trispecific T Cell Engager in Patients Relapsed after Anti-CD38 and Anti-BCMA Targeted Immunotherapies

Alana Keller, Olivia Perez De Acha, Lauren T Reiman, Zachary J Walker, David S Jayabalan, Ruben Niesvizky, Peter A Forsberg, Peter Kim, Kamlesh Bisht, Hongfang Wang, Helgi van de Velde, Daniel W. Sherbenou

Blood (2022) 140 (Supplement 1): 7097–7099.

https://doi.org/10.1182/blood-2022-169072

Published: 2022

Journal Articles

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Blood (2021) 137 (13): 1792–1803.

https://doi.org/10.1182/blood.2020007233

Published: 2021

Includes: Supplemental data

Journal Articles

Longitudinal Molecular Profiling in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib

Sung Choe, PhD, Hongfang Wang, PhD, Gail J. Roboz, MD, Courtney D. DiNardo, MD MSCE, Eytan M. Stein, MD, Alice S. Mims, MD, Gabrielle T. Prince, MD, Justin M. Watts, MD, Bin Fan, PhD, Parham Nejad, BSc, Vickie Zhang, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Bin Wu, PhD, Richard M. Stone, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136589

Published: 2020

Journal Articles

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1 -mutant acute myeloid leukemia

Blood (2020) 135 (7): 463–471.

https://doi.org/10.1182/blood.2019002140

Published: 2020

Includes: Supplemental data

Journal Articles

Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Analyses

Hongfang Wang, PhD, Sung Choe, PhD, Courtney D. DiNardo, MD MSc, Eytan M. Stein, MD, Stéphane de Botton, MD PhD, Amir T. Fathi, MD, Martin S. Tallman, MD, Hagop M. Kantarjian, MD, Richard M. Stone, MD, Lynn Quek, MD PhD, Vickie Zhang, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Bin Wu, PhD

Blood (2019) 134 (Supplement_1): 541.

https://doi.org/10.1182/blood-2019-122703

Published: 2019

Journal Articles

Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia

Sung Choe, PhD, Hongfang Wang, PhD, Courtney D. DiNardo, MD MSc, Eytan M. Stein, MD, Stephane De Botton, Amir T. Fathi, MD, Martin S. Tallman, MD, Hagop M. Kantarjian, MD, Richard M. Stone, MD, Lynn Quek, MD PhD, Zenon Konteatis, PhD, Lenny Dang, PhD, Vickie Zhang, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Bin Wu, PhD

Blood (2019) 134 (Supplement_1): 545.

https://doi.org/10.1182/blood-2019-122671

Published: 2019

Journal Articles

Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of the Day 14 Bone Marrow Biopsy

Emily F Mason, MD PhD, Olga Pozdnyakova, MD PhD, Mikhail Roshal, MD PhD, Amir T. Fathi, MD, Eytan M. Stein, MD, Aaron C. Shaver, MD PhD, Mark G. Frattini, MD, Hongfang Wang, PhD, Lei Hua, PhD, Jimmy Mu, Caroline Almon, MS, Michael Cooper, MD, Richard M. Stone, MD, Robert P. Hasserjian, MD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 1442.

https://doi.org/10.1182/blood-2019-123845

Published: 2019

Journal Articles

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 4254.

https://doi.org/10.1182/blood-2019-123946

Published: 2019

Journal Articles

Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions

Blood (2018) 132 (Supplement 1): 560.

https://doi.org/10.1182/blood-2018-99-110449

Published: 2018

Journal Articles

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study

Blood (2018) 132 (Supplement 1): 561.

https://doi.org/10.1182/blood-2018-99-110595

Published: 2018

Journal Articles

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study

Blood (2018) 132 (Supplement 1): 1812.

https://doi.org/10.1182/blood-2018-99-111264

Published: 2018

Journal Articles

Genetic Profiling and Deep IDH1 Mutation Clearance to ≤0.04% in Ivosidenib (AG-120)-Treated Patients with Mutant IDH1 Relapsed or Refractory and Untreated AML

Richard M. Stone, MD, Sung Choe, PhD, Vickie Zhang, PhD, Benoit Marteyn, PhD, Virginie Penard-Lacronique, PhD, Hongfang Wang, PhD, Courtney D. DiNardo, MDMSc, Eytan M. Stein, MD, Amir T. Fathi, MD MD BS, Martin S. Tallman, MD, Hagop M. Kantarjian, MD, Eyal C. Attar, MD, Bin Wu, Stephane de Botton, MD PhD

Blood (2017) 130 (Supplement 1): 2684.

https://doi.org/10.1182/blood.V130.Suppl_1.2684.2684

Published: 2017

Journal Articles

Alternative Super-Enhancer States Determine MYC Sensitivity to Notch and Brd4 Inhibitors in T Lymphoblastic Leukemia/Lymphoma

Hongfang Wang, PhD, Yumi Yashiro-Ohtani, PhD, Chongzhi Zang, PhD, Yinling Joey Wong, MS, Will Bailis, PhD, Birgit Knoechel, MD PhD, Bradley Bernstein, MD PhD, Steve Blacklow, MD PhD, X. Shirley Liu, PhD, Warren S. Pear, MD PhD, Jon C Aster, MD PhD

Blood (2014) 124 (21): 863.

https://doi.org/10.1182/blood.V124.21.863.863

Published: 2014

Journal Articles

RUNX1 Is Required For Maintenance Of Established T-ALL Blasts

Christopher R Jenkins, Olena O Shevchuk, Hongfang Wang, Ph.D., Vincenzo Giambra, PhD, Samuel D Gusscott, Jon C. Aster, MD, PhD, Andrew P Weng, MD, PhD

Blood (2013) 122 (21): 3742.

https://doi.org/10.1182/blood.V122.21.3742.3742

Published: 2013

Journal Articles

Genome-Wide Analysis of NOTCH1, ETS Family Factors, and RUNX1 Binding in Human T Lymphoblastic Leukemia Cells Reveals Distinct Regulatory Elements

Hongfang Wang, PhD, Chongzhi Zang, Ph.D, Len Taing, Hoifung Wong, Yumi Yashiro-Ohtani, Ph.D., Stephen Blacklow, MD. PhD., Warren S. Pear, MD, PhD, X. Shirley Liu, Ph.D, Jon C Aster, MD, PhD

Blood (2012) 120 (21): 1277.

https://doi.org/10.1182/blood.V120.21.1277.1277

Published: 2012

Journal Articles

Collaboration Between RUNX and NOTCH Pathways in T-Cell Acute Lymphoblastic Leukemia

Christopher R Jenkins, Hongfang Wang, PhD, Olena O Shevchuk, Sonya H Lam, Vincenzo Giambra, PhD, Louis Wang, Samuel D Gusscott, Jon C Aster, MD, PhD, Andrew P Weng, MD, PhD

Blood (2012) 120 (21): 1279.

https://doi.org/10.1182/blood.V120.21.1279.1279

Published: 2012

Journal Articles

Genome-Wide Analysis Reveals Conserved and Divergent Features of Notch1/RBPJ Binding in Human and Murine T Lymphoblastic Leukemia Cells

Jon C Aster, MD, PhD, Hongfang Wang, Ph.D., James Zou, Yumi Yashiro-Ohtani, Ph.D., Bo Zhao, Ph.D., Eric Johannsen, MD, Jonathan Schug, Ph.D., Stephen C. Blacklow, MD, PhD, Elliott Kieff, MD, PhD, Warren S. Pear, MD, PhD

Blood (2011) 118 (21): 5236.

https://doi.org/10.1182/blood.V118.21.5236.5236

Published: 2011

NARROW

A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent in Multiple Myeloma Patients Relapsed and/or Refractory (RRMM) to Anti-CD38 Monoclonal Antibodies (mAbs)

A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent for the Treatment of Older Patients with Acute Myeloid Leukemia (AML)

The CD38/CD3xCD28 Trispecific Antibody (SAR442257) Potentially Represents a Novel Therapeutic Strategy for Peripheral T-Cell Lymphomas

High Ex Vivo Response Rates to CD38/CD28xCD3 Trispecific T Cell Engager in Patients Relapsed after Anti-CD38 and Anti-BCMA Targeted Immunotherapies

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Longitudinal Molecular Profiling in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1 -mutant acute myeloid leukemia

Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Analyses

Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia

Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of the Day 14 Bone Marrow Biopsy

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study

Genetic Profiling and Deep IDH1 Mutation Clearance to ≤0.04% in Ivosidenib (AG-120)-Treated Patients with Mutant IDH1 Relapsed or Refractory and Untreated AML

Alternative Super-Enhancer States Determine MYC Sensitivity to Notch and Brd4 Inhibitors in T Lymphoblastic Leukemia/Lymphoma

RUNX1 Is Required For Maintenance Of Established T-ALL Blasts

Genome-Wide Analysis of NOTCH1, ETS Family Factors, and RUNX1 Binding in Human T Lymphoblastic Leukemia Cells Reveals Distinct Regulatory Elements

Collaboration Between RUNX and NOTCH Pathways in T-Cell Acute Lymphoblastic Leukemia

Genome-Wide Analysis Reveals Conserved and Divergent Features of Notch1/RBPJ Binding in Human and Murine T Lymphoblastic Leukemia Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only